Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy

Journal of Viral Hepatitis

Volumn 20, Issue 12, 2013, Pages 858-866

  Clark, P J ^a,b,c   Aghemo, A ^d   Degasperi, E ^d   Galmozzi, E ^d   Urban, T J ^e   Vock, D M ^a   Patel, K ^a   Thompson, A J ^a   Rumi, M G ^d   D'Ambrosio, R ^d   Muir, A J ^a   Colombo, M ^d  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MILAN   (Italy)

^e DUKE UNIVERSITY   (United States)

Author keywords

erythropoietin; inosine triphosphatase; ribavirin induced haemolysis; single nucleotide polymorphism

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; DRUG DOSE REDUCTION; FEMALE; GENE; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; INOSINE TRIPHOSPHATASE DEFICIENCY; INOSINE TRIPHOSPHATASE GENE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ERYTHROPOIETIN; INOSINE TRIPHOSPHATASE; RIBAVIRIN-INDUCED HAEMOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANEMIA; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; METABOLISM, INBORN ERRORS; MIDDLE AGED; PYROPHOSPHATASES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84887611639     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12113     Document Type: Article

References (30)

1. Fried MW,. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (5 Suppl. 1): S237-S244.
2. Stickel F, Helbling B, Heim M, et al,. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. J Viral Hepatitis 2011; 19 (2): 77-87.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
4. Hezode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360 (18): 1839-1850.
5. McHutchison JG, Manns M, Patel K, et al,. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123 (4): 1061-1069.
6. Reddy KR, Shiffman ML, Morgan TR, et al,. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5 (1): 124-129.
7. Dieterich DT, Wasserman R, Brau N, et al,. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98 (11): 2491-2499.
8. Afdhal NH, Dieterich DT, Pockros PJ, et al,. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126 (5): 1302-1311.
9. Del Rio RA, Post AB, Singer ME,. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006; 44 (6): 1598-1606.
10. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R,. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepatitis 2004; 11 (3): 243-250.
11. Shiffman ML, Ghany MG, Morgan TR, et al,. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132 (1): 103-112.
12. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM,. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol 2008; 103 (8): 1981-1988.
13. Fellay J, Thompson AJ, Ge D, et al,. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464 (7287): 405-408.
14. Thompson AJ, Fellay J, Patel K, et al,. Variants in the ITPA Gene Protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139 (4): 1181-1189.
15. Thompson AJ, Santoro R, Piazzolla V, et al,. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 2011; 53 (2): 389-395.
16. Chayama K, Hayes CN, Abe H, et al,. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204 (1): 84-93.
17. Suzuki F, Suzuki Y, Akuta N, et al,. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011; 53 (2): 415-421.
18. Sulkowski MS, Reddy KR, Pedicone LD, et al,. ITPA deficiency is associated with lower rates of anemia and EPO use in patients treated with Boceprevir (BOC) plus Peginterferon/Ribavirin (PR). Available at: http://www.natap.org/2011/AASLD/AASLD-89.htm.
19. Kurosaki M, Tanaka Y, Tanaka K, et al,. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. Antivir Ther 2011; 16 (5): 685-694.
20. Tanaka Y, Kurosaki M, Nishida N, et al,. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet 2011; 20 (17): 3507-3516.
21. Ochi H, Maekawa T, Abe H, et al,. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139 (4): 1190-1197.
22. Lotsch J, Hofmann WP, Schlecker C, et al,. Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy. Pharmacogenomics 2011; 12 (12): 1729-1740.
23. Rodriguez S, Gaunt TR, Day IN,. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169 (4): 505-514.
24. Reddy KR, Nelson DR, Zeuzem S,. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol 2009; 50 (2): 402-411.
25. Sulkowski MS, Shiffman ML, Afdhal NH, et al,. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139 (5): 1602-1611.e1.
26. Sievert W, Dore GJ, McCaughan GW, et al,. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology 2011; 53 (4): 1109-1117.
27. Sulkowski M, Poordad F, Manns M, et al,. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment failure patients. J Hepatol 2011; 54 (Suppl. 1): S194.
28. Hézode C,. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver Int 2012; 32: 32-38.
29. De Franceschi L, Fattovich G, Turrini F, et al,. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31 (4): 997-1004.
30. Hitomi Y, Cirulli ET, Fellay J, et al,. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 2011; 140 (4): 1314-1321.